ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Recently, a novel variant of ER-alpha, ER-alpha36 was identified and cloned. ER-alpha36 lacks intrinsic transcription activity and mainly mediates nongenomic estrogen signaling. Here, we studied the role of nongenomic estrogen signaling pathways mediated by ER-alpha36 in tamoxifen resistance and ago...

Full description

Bibliographic Details
Main Authors: Sheng-Li Lin, Li-Ying Yan, Xin-Tian Zhang, Ju Yuan, Mo Li, Jie Qiao, Zhao-Yi Wang, Qing-Yuan Sun
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-02-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2814868?pdf=render

Internet

http://europepmc.org/articles/PMC2814868?pdf=render

Similar Items